Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
Trevena is a biopharmaceutical company focused on the development and commercializ...
Trevena is a biopharmaceutical company focused ...
Neuralstem is a biopharmaceutical company developing novel treatments for nervous ...
Neuralstem is a biopharmaceutical company devel...
We are a clinical stage biopharmaceutical company leveraging our two proprietary t...
We are a clinical stage biopharmaceutical compa...
DBV Technologies is developing ViaskinÂŽ, an investigational proprietary technolog...
DBV Technologies is developing ViaskinÂŽ, an in...
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focuse...
Royal Philips (NYSE: PHG, AEX: PHIA) is a leadi...
iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solut...
iCAD, Inc. an industry-leading provider of adva...
Fibrocell is a cell and gene therapy company focused on improving the lives of peo...
Fibrocell is a cell and gene therapy company fo...
Join the National Investor Network and get the latest information with your interests in mind.